These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30310464)

  • 1. Familial Hypercholesterolaemia Diagnosis and Management.
    Alonso R; Perez de Isla L; Muñiz-Grijalvo O; Diaz-Diaz JL; Mata P
    Eur Cardiol; 2018 Aug; 13(1):14-20. PubMed ID: 30310464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.
    Pećin I; Hartgers ML; Hovingh GK; Dent R; Reiner Ž
    Eur J Prev Cardiol; 2017 Sep; 24(13):1383-1401. PubMed ID: 28644091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial hypercholesterolaemia.
    Nair DR; Sharifi M; Al-Rasadi K
    Curr Opin Cardiol; 2014 Jul; 29(4):381-8. PubMed ID: 24870549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM; Stefanutti C; Sniderman A; Watts GF
    Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of familial hypercholesterolaemia.
    Hovingh GK; Davidson MH; Kastelein JJ; O'Connor AM
    Eur Heart J; 2013 Apr; 34(13):962-71. PubMed ID: 23416791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease.
    Kim EJ; Wierzbicki AS
    Ther Adv Chronic Dis; 2020; 11():2040622320924569. PubMed ID: 32537117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the detection of familial hypercholesterolaemia.
    Lan NSR; Martin AC; Brett T; Watts GF; Bell DA
    Pathology; 2019 Feb; 51(2):213-221. PubMed ID: 30579649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial hypercholesterolaemia.
    Defesche JC; Gidding SS; Harada-Shiba M; Hegele RA; Santos RD; Wierzbicki AS
    Nat Rev Dis Primers; 2017 Dec; 3():17093. PubMed ID: 29219151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia.
    Viigimaa M; Heinsar S; Lovic D; Katsimardou A; Piperidou A; Duishvili D
    Curr Pharm Des; 2018; 24(31):3599-3604. PubMed ID: 30306860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6th Hellenic Congress in Athens, of the Hellenic Atherosclerosis Society, on the 04-06 December 2014 Novel Pharmacologic Treatments of Familial Hypercholesterolaemia.
    Athyros VG
    Open Cardiovasc Med J; 2015; 9():73-7. PubMed ID: 26664657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.